Glaxosmithkline Consumer Healthcare Holdings DBA Haleon: Drug Recall

Recall #D-0181-2023 · 12/06/2022

Class I: Dangerous

Recall Details

Recall Number: D-0181-2023
Classification: Class I
Product Type: Drug
Recalling Firm: Glaxosmithkline Consumer Healthcare Holdings DBA Haleon
Status: Terminated
Date Initiated: 12/06/2022
Location: Warren, NJ, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 321,246 tablets

Reason for Recall

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Product Description

Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573 0154 60 4), and b) 200-count bottles (UPC 3 0573 0154 21 5), Pfizer, Madison, NJ 07940

Distribution Pattern

Nationwide in the USA.

Other Recalls by Glaxosmithkline Consumer Healthcare Holdings DBA Haleon

Class I: Dangerous 12/06/2022

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Class I: Dangerous 12/06/2022

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

View all recalls by Glaxosmithkline Consumer Healthcare Holdings DBA Haleon →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.